Targeted Metallo-Drugs

<p>Volume 24 entitled <em>Targeted Metallo-Drugs: Design Development and Modes of Action</em> of the series <em>Metal Ions in Life Sciences </em>(MILS) fosters inter-disciplinary research in the vibrant field of <i>Biological Inorganic Chemistry</i>. Inspired by the clinical success of cisplatin as a leading anticancer drug but mindful of the shortcomings associated with its use including dose-limiting toxic side effects and acquired or intrinsic drug resistance scientists across the globe have been endeavoring to identify new metallo-drugs for therapeutic exploitation. This has led to innovative metallo-drug candidates that (i) enhance cancer cell selectivity thus reducing toxic side effects and/or (ii) possess new modes of action to improve efficacy and also target resistance pathways. This and more are captured in MILS- 24 which consists of 12 comprehensive well-illustrated and up to date chapters with over <b>1600 </b>citations <b>100 </b>figures and <b>10 </b>tables with key contributions from <b>32 </b>international experts from Europe Asia and North and South America. MILS- 24 not only keeps the scientific community abreast of latest developments it also serves as an invaluable resource to stimulate further research on targeted metallo-drug design and development.</p><ul> <li>It covers anticancer antimicrobial antiviral and other agents such as those targeting tropical diseases and cyanide poisoning and radiometals in molecular imaging and therapy</li> <li>It highlights recent metallo-drug developments targeting COVID-19</li> <li>It features advanced spectroscopic methods and metallomics as important tools to elucidate the modes of actions of metallo-drugs</li> </ul>